DEFA14A: Aclarion Adjourns Annual Meeting to Solicit Additional Votes

Aclarion, Inc. has adjourned its Annual Meeting of Stockholders to July 21, 2025, to solicit additional votes for the proposals outlined in its definitive proxy statement.

Summary

• Aclarion has adjourned its Annual Meeting of Stockholders, originally scheduled for July 7, 2025.
• The meeting has been reconvened for July 21, 2025, at 9:30 a.m. Mountain Time.
• The purpose of the adjournment is to solicit additional votes regarding the proposals detailed in the company's definitive proxy statement filed with the SEC on May 13, 2025.
• The meeting will be held at Aclarion's corporate office in Broomfield, Colorado.
• The record date for determining stockholders eligible to vote remains May 9, 2025.
• Stockholders who have already submitted their proxies do not need to take further action unless they wish to change their vote.
• Stockholders can change their vote until 11:59 p.m. Mountain Time on July 20, 2025.

Sentiment

Score: 5

Explanation: The document is a neutral announcement about the adjournment of the annual meeting.

Positives

• Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

Risks

• The forward-looking statements are subject to risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including those discussed under the heading Risk Factors in our most recently filed reports on Forms 10-K and 10-Q.

Future Outlook

The document contains forward-looking statements regarding the Annual Meeting and the company's future operations, which are subject to risks and uncertainties.

Industry Context

Aclarion is operating in the healthcare technology sector, specifically targeting the low back and neck pain market, which is estimated to be a $134.5B market in the U.S. The company is leveraging Magnetic Resonance Spectroscopy (MRS) and artificial intelligence to optimize clinical treatments.

Stakeholder Impact

• Shareholders are encouraged to vote on the proposals.
• The adjournment allows more time for shareholders to participate in the voting process.

Next Steps

• Stockholders are encouraged to vote as soon as possible.
• The company will reconvene the Annual Meeting on July 21, 2025.
• The company will continue to solicit votes with respect to the proposals described in the definitive proxy statement.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Adjournment, Voting, Aclarion, MRS, AI, Healthcare Technology